Nasdaq:US$11.88 (+0.00) | HKEX:HK$19.10 (+0.12) | AIM:£1.91 (-0.05)
News & Presentations
Previous Article   |   Next Article
Presentations | 18 Apr 2023

AACR 2023: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies